Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 , an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
Domestic Metals Completes Surface IP Geophysical Survey at Smart Creek and Announces Amendment to Warrant Terms of Unit Private Placement
RETRANSMISSION: West High Yield Resources Ltd. Signs Definitive Forward Sales Agreement to Sell Magnesium Ore from Its Record Ridge Project
Anteros Metals Reports Assay Results from RM26-01 and Provides Exploration Update at the Seagull Critical Minerals Project, Ontario
